Monsanto Company (NYSE: MON) and ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, announced today that the companies have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop agricultural products.

ToolGen is an early pioneer in gene editing research. The license provides Monsanto with access to ToolGen’s comprehensive suite of CRISPR intellectual property for use in plants. This agreement further expands Monsanto’s broad portfolio of gene-editing tools that can be used to develop improved and sustainable crops.